"Closed-Loop Insulin Delivery Improves Glucose Control In Noncritical Care Setting" - Regina Schaffer
In hospitalized patients with type 2 diabetes receiving noncritical care — including dialysis and glucocorticoid therapy — use of a fully automated, closed-loop insulin-delivery system resulted in better glycemic control compared with standard insulin therapy. “This is a very important study for a few different reasons. First, the quality of glucose control in the inpatient setting has been a challenge for years, and there have been presentations on this problem at ADA. In my mind, what was exciting about this particular study was the use of closed-loop systems in the inpatient setting, which is relatively new; the use of it in patients with type 2 diabetes; and a comparator group that was so poorly controlled,” said Carol Levy, MD, CDE, associate professor of endocrinology, diabetes, and bone disease at the Icahn School of Medicine at Mount Sinai and director of the Mount Sinai Diabetes Center. “In this study, the researchers used close-loop with no user input. Most artificial pancreas systems out there are used by those with type 1 diabetes and require user input. So, this is potentially a huge area, and you see here that 65 percent of these patients were in range vs. the comparator group.”
- Carol Levy, MD, CDE, Associate Professor, Endocrinology, Diabetes and Bone Disease, Obstetrics, Gynecology and Reproductive Science, Director, Mount Sinai Diabetes Center, T1 Diabetes Clinical Research, Icahn School of Medicine at Mount Sinai